MHRA says non-arteritic anterior ischemic optic neuropathy (NAION) has been very rarely reported with semaglutide and has updated product information for Wegovy, Ozempic, and Rybelsus accordingly. The agency advises urgent ophthalmology referral for patients who develop sudden vision loss or deterioration, and says semaglutide should be discontinued if NAION is confirmed.
This matters for pharmacovigilance because it shows how a rare but serious event can change both product information and clinical handling advice. It is also a reminder that safety communication increasingly has to account for real-world prescribing patterns, including private prescribing that may not appear clearly in a patient’s medical history.
For PV teams, the bigger lesson is that signal management is not only about identifying a pattern. It is also about translating that pattern into practical action for clinicians, patients, and safety systems
0 Comments